Anavex Expanding Boundaries
        in Drug Discovery
HOME  |  ABOUT US  |  PIPELINE  |  R & D  |  PUBLICATIONS  |  PARTNERING  |  INVESTORS  |  CAREERS  |  CONTACT
LATEST NEWS
2/14/2012
Anavex to present corporate update at BIO CEO & Investor Conference
11/14/2011
Anavex successfully completes a Phase 1 clinical trial for ANAVEX 2-73
10/12/2011
Anavex appoints Dr. George Tidmarsh as Executive Director
Anavex Corporate Update
BIO CEO & Investor Conference
February 14, 2012
CORPORATE BROCHURE
MEDIA COVERAGE
Alzheimer’s Treatment
Showcase Is Set
News Makers: Also Friday
News in the healthcare sector
EMAIL UPDATES

 

Anavex Life Sciences Corp. has a productive drug discovery platform with a broad IP portfolio based on unique expertise of sigma receptors ligands. ANAVEX 2-73 has succesfully completed a Phase 1 single ascending dose clinical trial of ANAVEX 2-73, lead drug candidate for the treatment of Alzheimer’s Disease (AD). Several other new drug candidates with high affinity for sigma receptors are close to entering Phase 1 clinical trials. The synergetic effects of sigma receptors offer a new neuroprotective mechanism in AD and other Central Nervous System disorders such as epilepsy and depression. Anavex proprietary sigma ligands induce apoptosis in cancer cells in a selective way. Anavex oncology candidates show promising pro-apoptotic activity in several in vivo models of solid tumors.

According to 2011 Alzheimer’s Disease Facts and Figures, released by the Alzheimer’s Association, there are nearly 15 million Alzheimer’s and dementia caregivers in the United States. This new report shows that there are far more Alzheimer’s and dementia caregivers than previously believed – 37% more than reported last year. These individuals provided 17 billion hours of unpaid care valued at $202.6 billion. If Alzheimer’s and dementia caregivers were the only residents of a single state it would be the 5th largest state in the country. more

ARTICLES ON ALZHEIMER’S
A rich portfolio of drug candidates with new mechanism of action, targeting Alzheimer’s Disease and Cancer.
© 2007-2012 Anavex Life Sciences Corp. - All Rights Reserved.